BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35404082)

  • 1. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
    Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
    J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
    Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
    Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
    Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
    Front Immunol; 2018; 9():932. PubMed ID: 29765376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
    Cui X; Snapper CM
    Front Immunol; 2021; 12():734471. PubMed ID: 34691042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
    Perez EM; Foley J; Tison T; Silva R; Ogembo JG
    Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.
    Heeke DS; Lin R; Rao E; Woo JC; McCarthy MP; Marshall JD
    Vaccine; 2016 May; 34(23):2562-9. PubMed ID: 27085175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
    Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
    Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
    [No Abstract]   [Full Text] [Related]  

  • 9. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
    Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
    Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV.
    Sun C; Kang YF; Fang XY; Liu YN; Bu GL; Wang AJ; Li Y; Zhu QY; Zhang H; Xie C; Kong XW; Peng YJ; Lin WJ; Zhou L; Chen XC; Lu ZZ; Xu HQ; Hong DC; Zhang X; Zhong L; Feng GK; Zeng YX; Xu M; Zhong Q; Liu Z; Zeng MS
    Cell Host Microbe; 2023 Nov; 31(11):1882-1897.e10. PubMed ID: 37848029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies.
    Sathiyamoorthy K; Jiang J; Möhl BS; Chen J; Zhou ZH; Longnecker R; Jardetzky TS
    Proc Natl Acad Sci U S A; 2017 Oct; 114(41):E8703-E8710. PubMed ID: 28939750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.
    Tober R; Banki Z; Egerer L; Muik A; Behmüller S; Kreppel F; Greczmiel U; Oxenius A; von Laer D; Kimpel J
    J Virol; 2014 May; 88(9):4897-907. PubMed ID: 24554655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus.
    Zhong L; Krummenacher C; Zhang W; Hong J; Feng Q; Zhao Q; Chen Y; Zeng MS; Zeng YX; Xu M; Zhang X
    Virol J; 2022 Nov; 19(1):196. PubMed ID: 36424667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with a Self-Assembled Nanoparticle Vaccine Elicits Potent Neutralizing Antibody Responses against EBV Infection.
    Kang YF; Zhang X; Yu XH; Zheng Q; Liu Z; Li JP; Sun C; Kong XW; Zhu QY; Chen HW; Huang Y; Xu M; Zhong Q; Zeng YX; Zeng MS
    Nano Lett; 2021 Mar; 21(6):2476-2486. PubMed ID: 33683126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
    Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
    J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection.
    Hong J; Zhong L; Liu L; Wu Q; Zhang W; Chen K; Wei D; Sun H; Zhou X; Zhang X; Kang YF; Huang Y; Chen J; Wang G; Zhou Y; Chen Y; Feng QS; Yu H; Li S; Zeng MS; Zeng YX; Xu M; Zheng Q; Chen Y; Zhang X; Xia N
    Cell Rep Med; 2023 Nov; 4(11):101296. PubMed ID: 37992686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits.
    Escalante GM; Foley J; Mutsvunguma LZ; Rodriguez E; Mulama DH; Muniraju M; Ye P; Barasa AK; Ogembo JG
    Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32268575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of serum Epstein-Barr virus envelope glycoproteins antibodies and their association with systemic autoimmune diseases.
    Li HL; Zhong LY; Kang YF; Yang YL; Shi L; Zhai AX; Wu C; Zeng MS; Zhu QY
    J Med Virol; 2024 Apr; 96(4):e29595. PubMed ID: 38587217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.